The 2020 NCCN Guidelines for metastatic breast cancer underscore that advancements in systemic therapy, tailored to specific tumor biology, have driven substantial survival improvements. This paradigm shift reflects a more personalized, biomarker-driven approach to treatment selection and patient management.